BioCentury
ARTICLE | Clinical News

AP 12009: Phase I/II

May 26, 2003 7:00 AM UTC

In an ongoing Phase I/II dose-escalation study, AP 12009 was safe and well tolerated. In the study, 18 patients received a single course of intratumoral AP 12009, 2 patients received a second course o...